This contribution investigates the critical issue of ensuring the economic security of pharmaceutical companies, a sector that plays a key role in public health and the national economy. It examines the unique challenges faced by pharmaceutical companies, including regulatory pressure, market volatility, intellectual property protection, and supply chain vulnerabilities. By analyzing key risk factors and proposing practical solutions, the author provides insights into how pharmaceutical companies can improve their resilience, ensure sustainable growth, and remain competitive in a rapidly changing global market. Efficient use of resources, cost management and strengthening partnerships with stakeholders are also key components of ensuring economic security. The work concludes that ensuring economic security for pharmaceutical enterprises requires a multifaceted approach balancing innovation, compliance, financial stability and strategic risk management. By addressing these aspects, pharmaceutical companies can overcome challenges, protect their market position and contribute effectively to health systems while maintaining long-term viability. The results are intended to support industry leaders and stakeholders in developing frameworks that protect the economic interests of the pharmaceutical sector while promoting innovation and public health outcomes.